May 3, 2026 10 min read FDA & Policy FDA sets July 2026 PCAC review for key compounding peptides (BPC-157, MOTs-C, Semax) FDAs July 2324, 2026 PCAC agenda puts seven peptides (BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, E
Some users split their weekly retatrutide dose into smaller, more frequent injections to reduce peak-related side effects and maintain more stable drug levels
FDA Approved A ready-to-drink glutathione beauty formula designed to support brighter, smoother, and more hydrated skin, infused with pomegranate ferment, Vitamin C, and Vitamin E for antioxidant and skin-repair supportinside and out
Over 32 weeks, CagriSema produced HbA1c reductions of 2.2 percentage points compared to 1.8 with semaglutide alone and 0.9 with cagrilintide alone, with CagriSema statistically superior to cagrilintide